This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:APGE

Apogee Therapeutics (APGE) Stock Price, News & Analysis

Apogee Therapeutics logo

About Apogee Therapeutics Stock (NASDAQ:APGE)

Key Stats

Today's Range
$135.07
▼
$135.07
50-Day Range
$134.09
▼
$135.10
52-Week Range
$35.39
▼
$135.09
Volume
N/A
Average Volume
1.39 million shs
Market Capitalization
$8.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$126.77
Consensus Rating
Hold

Company Overview

Apogee Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach emphasizes therapies designed to offer extended dosing intervals, with the goal of improving convenience and treatment options for patients with chronic conditions.

Apogee’s lead program is APG777, a long-acting monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The program is being developed for conditions including atopic dermatitis, asthma and other inflammatory diseases. The company is also advancing APG808, an extended-half-life antibody targeting the interleukin-4 receptor alpha (IL-4Rα) pathway, which is implicated in several type 2 inflammatory disorders.

Apogee was established in 2022 and became a publicly traded company on the Nasdaq under the symbol APGE in 2023. The company is headquartered in San Francisco, California, and its development activities are focused on addressing unmet needs in inflammatory and immunologic diseases. Apogee is led by Chief Executive Officer Michael Henderson.

AI Generated. May Contain Errors.

Receive APGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APGE Stock News Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Headlines

APGE Stock Analysis - Frequently Asked Questions

Apogee Therapeutics Inc. (NASDAQ:APGE) issued its quarterly earnings results on Monday, August, 10th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.07) by $0.07.

Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Thursday, July 13th 2023. The company issued 17,650,000 shares at $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Atai Beckley (ATAI), BridgeBio Pharma (BBIO), Corbus Pharmaceuticals (CRBP), DraftKings (DKNG) and Exelixis (EXEL).

Company Calendar

Last Earnings
8/10/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:APGE
CIK
1974640
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

High Price Target
$160.00
Low Price Target
$89.00
Potential Upside/Downside
-6.1%
Consensus Rating
Hold
Rating Score (0-4)
2.16
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$255.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.88%
Return on Assets
-28.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.44
Quick Ratio
26.44

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$19.21 per share
Price / Book
7.03

Miscellaneous

Outstanding Shares
62,201,000
Free Float
47,086,000
Market Cap
$8.40 billion
Optionable
Optionable
Beta
0.33
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:APGE) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners